
Tsimikas on why Lp(a) HORIZON missed its endpoint despite strong Lp(a)-risk evidence
Louis shares a summary of Dr. Sam Tsimikas's comments on the pelacarsen HORIZON trial missing its primary endpoint. Evidence linking high Lp(a) to heart attack, stroke, PAD and aortic valve disease remains large, but most came from general populations before aggressive LDL lowering, and HORIZON patients were already aggressively treated.
